Free Trial
→ PH: Do THESE 4 things to your bank account now … (From Weiss Ratings) (Ad)tc pixel
NASDAQ:SPRC

SciSparc 11/18/2025 Earnings Report

SciSparc logo
$6.25 -0.47 (-6.99%)
Closing price 04:00 PM Eastern
Extended Trading
$6.48 +0.24 (+3.76%)
As of 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

SciSparc EPS Results

Actual EPS
-$27.73
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

SciSparc Revenue Results

Actual Revenue
$0.23 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

SciSparc Announcement Details

Quarter
Date
11/18/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

SciSparc Earnings Headlines

SciSparc (NASDAQ:SPRC) Shares Down 8.5% - What's Next?
May 5 at 2:09 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30758641
SciSparc’s NeuroThera-Backed Collaboration Spurs New Depression Therapy Patent Filing
March 16, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/scisparcs-neurothera-backed-collaboration-spurs-new-depression-therapy-patent-filing?utm_source=marketbeat.com&utm_medium=referral
No. You’re not imagining it…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
May 8 at 1:00 AM  |  Porter & Company (Ad)
SciSparc Ltd. Reports NeuroThera Labs' Patent Application for Innovative Depression Treatment Combining MEAI and PEA
March 16, 2026  |  quiverquant.comQ
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
March 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/16/3256253/0/en/scisparc-neurothera-labs-clearmind-medicine-collaboration-leads-to-patent-application-for-depression-therapy.html
SciSparc Ltd. Advances Collaboration with NeuroThera Labs Inc. and Clearmind Medicine Inc. for Novel Combination Therapy Targeting Obesity and MASLD.
March 12, 2026  |  quiverquant.comQ
See More SciSparc Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SciSparc? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SciSparc and other key companies, straight to your email.

About SciSparc

SciSparc (NASDAQ:SPRC) AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function. By harnessing acoustic pressure waves, the TR100 aims to promote neurogenesis and synaptic plasticity without the need for surgical intervention. SciSparc has obtained CE marking for its tSWS platform in the European Union and is actively pursuing clinical trials in indications such as post‐stroke motor rehabilitation, treatment‐resistant depression and other neurological disorders.

Serving both European and North American markets, SciSparc collaborates with academic institutions and clinical research centers to validate safety and efficacy in human subjects. Its Swiss headquarters oversees research and development, regulatory affairs and manufacturing partnerships, while its U.S. operations concentrate on clinical development and market access strategies. By integrating neuroscience research with advanced engineering, SciSparc aims to expand the availability of noninvasive neuromodulation therapies on a global scale.

View SciSparc Profile
Earnings Tools